September 22, 2008

HELIX RECEIVES APPROVAL TO OPEN SITES IN GERMANY FOR ITS ONGOING CLINICAL TRIAL WITH TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH ANO-GENITAL WARTS (PDF)

(Aurora, Ontario) – Helix BioPharma announced today that it has received the necessary regulatory approvals to open clinical sites in Germany to expand upon its clinical trial with Topical Interferon Alpha-2b in patients with ano-genital warts, which is presently underway in Sweden.